Sikorski K, Chmielewski S, Przybyl L, Heemann U, Wesoly J, Baumann M, Bluyssen HA. STAT1-mediated signal integration between IFN␥ and LPS leads to increased EC and SMC activation and monocyte adhesion. Am J Physiol Cell Physiol 300: C1337-C1344, 2011. First published February 23, 2011 doi:10.1152/ajpcell.00276.2010.-Inflammation plays an important role in host defenses against infectious agents and injury, but it also contributes to the pathophysiology of atherosclerosis. Signal transducer and activated transcription 1 (STAT1) has been identified as a point of convergence for the cross talk between the pro-inflammatory cytokine interferon ␥ (IFN␥) and the Toll-like receptor-4 (TLR4) ligand LPS in immune cells. However, there is no information available on the role of STAT1 in TLR4-mediated progression of atherosclerosis and on potential synergism between lipopolysaccharides (LPS) and IFN␥ signaling in cells from the vasculature. Cultured human microvascular endothelial cells (HMECs) exposed to LPS activated STAT1 in a delayed manner that was inhibited by cycloheximide treatment. Pretreatment of HMECs as well as primary vascular smooth muscle cells (VSMCs) with IFN␥ followed by LPS resulted in a significant increase in STAT1 phosphorylation compared with both factors alone. Increased STAT1 protein levels, strictly mediated by IFN␥, correlated with the augmented STAT1 phosphorylation that was absent in TLR4 Ϫ / Ϫ cells. As assessed by PCR, Western analysis, and ELISA, this coincided with increased expression of the chemokine interferon gamma-induced protein 10 kDa (IP-10) and the adhesion molecule ICAM-1 in a TLR4-dependent manner.The STAT1-inhibitor fludarabine markedly reduced these effects as well as IFN␥ and LPS-dependent adhesion of U937 cells to endothelial cells, emphasizing the potential importance of STAT1 in the integration of both signals. With the established roles of IFN␥ and TLRs in atherosclerotic pathology, the STAT1-dependent signal integration between IFN␥ and TLR in ECs and VSMCs in response to exogenous and endogenous atherogenic ligands could result in amplification of pro-inflammatory responses in the damaged vessel and be a novel mechanism involved in the initiation and progression of atherosclerosis.
INFLAMMATION participates importantly in host defenses against infectious agents and injury, but it also contributes to the pathophysiology of atherosclerosis. Endothelial cells (ECs) play a crucial role in maintaining normal vessel wall function by their ability to inhibit thrombus formation, leukocyte adhesion, vascular smooth muscle cell (VSMC) proliferation, and by regulation of vessel tone. Pro-inflammatory stimuli trigger the endothelium to produce cell surface adhesion molecules, chemokines, and inflammatory cytokines, characteristic parameters of endothelial dysfunction (12) . Subsequent recruitment of blood leukocytes to the injured vascular endothelium and VSMC proliferation characterizes the initiation and progression of atherosclerosis (28) .
The pro-inflammatory cytokine interferon (IFN)␥, derived from T cells and natural killer cells (NK cells), is vital for both innate and adaptive immunity by activating macrophages, NK cells, B cells, ECs, and VSMCs. Evidence that IFN␥ is necessary and sufficient to cause vascular remodeling is supported by mouse models of atheroma, as the serological neutralization or genetic absence of IFN␥ markedly reduces the extent of atherosclerosis (18) . In addition, IFN␥ induces chemokine production, adhesion, apoptosis, and matrix deposition (30) . The signal transduction pathway initiated by binding of IFN␥ to its receptor leads to rapid intracellular phosphorylation and activation of signal transducer and activator of transcription (STAT)1 (35) . As such, IFN␥ is considered to participate in promoting atherogenic responses through STAT1-mediated "damaging" signals, which play a major role in driving the immune and pro-inflammatory responses leading to EC dysfunction, VSMC proliferation, and vascular damage (32) .
More recent studies in macrophages and dendritic cells have also revealed that STAT1 is involved in the signaling events mediated by Toll-like receptor 4 (TLR4), which is an innate immune pattern recognition receptor that is activated by lipopolysaccharides (LPS) (1) . TLR4 is expressed on a variety of cells, including ECs and VSMCs, and thus initiates and sustains the inflammatory response in atherosclerosis (2) . TLR4 signaling leads to the induction of various target genes that include those encoding type I interferons (IFNs), pro-inflammatory cytokines, chemokines, and cell surface molecules. Some of these genes are regulated in a delayed manner, which is mediated by the induction and subsequent autocrine activities of type I IFN in a STAT1-dependent manner (14) .
Consequently, STAT1 has been identified as a point of convergence for the cross talk between IFN␥ and LPS in immune cells (25) , which is considered relevant for the efficient induction of inflammatory mediators to eliminate pathogens. However, there is no information available on the role of STAT1 in TLR4-mediated progression of atherosclerosis and on potential synergism between LPS-and IFN␥-signaling in cells from the vasculature.
We provide evidence that in ECs and VSMCs in vitro STAT1-dependent functions of IFN␥ supply a platform for increased LPS signaling, resulting in augmented STAT1 phosphorylation and expression of intercellular adhesion molecule (ICAM)-1 and the chemokine interferon gamma-induced protein 10 kDa (IP-10). Fludarabine, a purine analog with immu-nosuppressive activity through the specific inhibition of STAT1 signaling (9, 32) , markedly reduced these effects as well as IFN␥ and LPS-dependent adhesion of monocytes to ECs.
MATERIALS AND METHODS
Reagents. Recombinant IFN␥ was purchased from Millipore, and LPS (Escherichia coli 0111:B4) was from Sigma. Cycloheximide was from Bioshop (Canada). Fludarabine was kindly provided by Dept. of Hematology, Medical University, Poznan, Poland.
Rabbit polyclonal antibodies against p-Tyr (701) STAT1, STAT1, interferon regulatory factor 1 (IRF1), IP-10, and ICAM-1 and mouse antibody against GAPDH and horseradish peroxidase (HRP)-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology. ␣-Tubuline antibody was purchased from Sigma.
Cell culture. Human microvascular endothelial cells (HMEC) were generously provided by the Center for Disease Control and Prevention (Atlanta, GA) and cultured as described (3) in MCDB-131 (IITD PAN, Wroclaw, Poland) medium containing 10% fetal calf serum (FCS) (Invitrogen), 100 U/ml penicillin, 100 g/ml streptomycin, 0.01 g/ml EGF, 0.05 M hydrocortisone, and 2 mM L-glutamine: MCDB-10%. Human leukemia U937 suspension cells were cultured in DMEM (IITD PAN) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% FBS. Mouse aortic VSMC were cultured in DMEM (Biochrom) medium containing 10% FBS (Sigma-Aldrich, Munich, Germany) and 2 mM L-glutamine (Biochrom) supplemented with 100 U/ml penicillin and 100 g/ml streptomycin. VSMC were isolated from C57BL/6 or TLR4 Ϫ/Ϫ mice using the protocol according to Kobayashi et al. (16) . Homogeneity of the culture was assessed by the expression of ␣-smooth muscle actin (5=-CAACTGGTATTGTGCTGGACT-3=; 5=-GAAAGATGGCTG-GAAGAGAGT-3=), calponin (5=-ACGGCTTGTCTGCTGAAGTA-3=; 5=-AAGATGTCGTGGGGTTTCAC-3=), and smoothelin (5=-AGAACTGGCTACACTCTCAAC-3=; 5=-GGGTCCAATGTGTGT-GCTG-3=).
In general, HMEC or VSMC treatment with 10 ng/ml of IFN␥ and/or 1 g/ml of LPS, as well as 75 g/ml of cycloheximide and 100 M fludarabine, was performed in serum-starved medium (containing 2% serum) after starvation of at least 16 h before an experiment.
From wild-type (WT) and TLR4 Ϫ/Ϫ VSMCs (n ϭ 4), RNA was isolated using RNeasy Mini Kit (QIAGEN, Hilden, Germany) and transcribed into cDNA with iScript cDNA synthesis kit (Bio-Rad) following the manufacturer's protocols. From HMECs total RNA was isolated using GeneMATRIX Universal RNA Purification Kit (Eurx, Gdansk, Poland). For RT 500 ng of total RNA was used and transcribed using RevertAid First Strand cDNA synthesis kit (Fermentas) and random hexamer primers.
Western blot analysis. HMECs were lysed using RIPA buffer (50 mM Tris·HCl, pH ϭ 8.0, 150 mM NaCl, 1% Nonidet-40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitor cocktail), VSMCs using Lysis-M Reagent (Roche) containing protease and phosphatase inhibitors (Roche), and stored at Ϫ80°C. Twenty micrograms of protein were boiled with sample buffer (except for ICAM-1; samples were run under nonreducing conditions) and loaded on a 10% acrylamide gel, electrophoresed, and transferred onto PVDF membranes (generally, 0.45 m pore size was used, except for IP-10 0.2 m) using a semidry transfer system (Hoefer). Membranes were blocked in 5% nonfat dry milk in TBS-Tween (TBS-T) and incubated with primary antibodies (1:200 pSTAT1, 1:500 STAT1, 1:200 IRF1, 1:100 IP-10, 1:200 ICAM-1, 1:2,000 GAPDH, 1:200 ␣-tubuline). After being washed three times in TBS-T, the membrane was incubated with goat anti-mouse or goat anti-rabbit HRP-conjugated (1: 20,000) antibody and then washed three times in TBS. Bound proteins were detected with Immobilon Western chemiluminescent substrate (Millipore). Membranes were stripped with buffer containing 25 mM glycin and 1% SDS, pH 2.0, and then reprobed. The intensity of each band was quantified using Photoshop and normalized to the level of GAPDH protein. Results are expressed as means (P-STAT1/STAT1, P-STAT1/GAPDH,STAT1/GAPDH, IP-10/GAPDH, or ICAM1/ GAPDH) Ϯ SE of at least three independent experiments.
ELISA. Murine IP-10 ELISA development kit was obtained from Peprotech (Hamburg, Germany) and was used according to the manufacturer's instruction.
Gene expression analyses by qPCR and PCR. QPCR on VSMCs was performed using a MyiQ Real Time PCR detection system provided by Bio-Rad. Data were normalized to the level of GAPDH expression and were evaluated in Bio-Rad iQ5 software. The primers used were the following: GAPDH, 5=-TCGGTGTGAACGGATTTGGC-3= and 5=-TGATGTTAGTGGGGTCTCGC-3=; IP-10, 5=-TCATCCCTGCGAGC-CTATCC-3= and 5=-GGAGCCCTTTTAGACCTTTTT-3=.
For qPCR experiments conducted on HMECs (see Fig. 2B ), 7900HT real-time PCR system (Applied Biosystems) and Maxima SYBR Green/ ROX qPCR MasterMix (Fermentas) were used. The amount of target gene in each subject was normalized to endogenous control ACT-␤ (⌬CT). Gene expression is expressed as means Ϯ SE of three independent experiments. Data were transformed as described (36) . The primers used were the following: ACT-␤, 5=-ACAGAGCCTCGCCTTTGC-CGAT-3= and 5=-ATCATCCATGGTGAGCTGGCGG-3=; IP-10, 5=-GCAGAGGAACCTCCAGTCTCAGCA-3= and 5=-AGAGAGAGG-TACTCCTTGAATGCCAC-3=, ICAM-1, 5=-CAGCGGCTGACGTGT-GCAGTAA-3= and 5=-TTGGGCGCCGGAAAGCTGTA-3=.
Regular (semiquantitative) PCR (see Figs. 1C and 3D) was conducted using Allegro Taq (Novazym, Poznan, Poland). Primers used were as follows: 18S, 5=-AGTTGGTGGAGCGATTTGTC-3= and 5=-TATT-GCTCAATCTCGGGTGG-3=, IP-10, 5=-GACTCTAAGTGGCATT-CAAG-3= and 5=-TCAGACATCTCTTCTCACCC-3=, ICAM-1, 5=-TGACCATCTACAGCTTTCCG-3= and 5=-TCTTGTGTATAAGCTG-GCCG-3=.
Adhesion assay. HMEC cells were seeded onto six-well plates and grown to 80 -90% confluence. The cells were starved for at least 16 h. Cells were treated with IFN␥ and LPS as described above. The cells were left on the plates for 12 h after treatment. U937 cells were labeled with MTT according to Miki et al. (20) , albeit the cells were incubated with MTT for 1.5 h. After labeling was completed, 1 ϫ 10 6 cells were resuspended in 2 ml of fresh medium and added to each well of treated HMECs, from which the medium was removed. After 45 min of incubation at 37°C, cells were washed with PBS and 1 ml of DMSO was added and incubated for another 20 min. Next, the absorbance was measured at 540 nm using Lambda EZ150 (Perkin Elmer) spectrophotometer. A calibration curve of various amounts of labeled U937 cells (5, 15, 45, 150 , 500 ϫ 10 3 ) was used to calculate the number of adhered cells. Data are expressed as a percentage of basal adhesion of U937 cells to untreated HMECs.
Data analysis. Results are expressed as means Ϯ SE. Data were compared by a one-way ANOVA and the Tukey HSD post hoc test, when appropriate. All statistical tests were performed with Statistica software (Statsoft); P Ͻ 0.05 was considered significant.
RESULTS

LPS-induced activation of STAT1 and target gene expression in endothelial cells. Treatment of HMECs with LPS
resulted in STAT1 phosphorylation in a time-dependent fashion (Fig. 1A) and dose-dependent fashion (not shown). STAT1 phosphorylation was only detectable after 4 h of exposure to 1 g/ml LPS (not using 0.1 or 0.3 g/ml: not shown), decreased after 8 h, and was hardly detectable at 24 h. LPS did not affect total amounts of STAT1 protein at these time points. In contrast, IFN␥-induced STAT1 phosphorylation in HMECS occurs rapidly (within 30 min) and results in a time-dependent increase of STAT1 protein (see Ref. 3 and data not shown).
Next, we treated HMECs with LPS for 4 h in the absence or presence of cycloheximide (pretreated for 1 h). Figure 1B shows that LPS-induced STAT1 phosphorylation (lane 3) as well as expression of the STAT1-target IRF1 is blocked in the presence of cycloheximide (lane 4), which correlates with a protein synthesis-dependent mechanism. Indeed, LPS-dependent IFN␤ expression preceded STAT1 phosphorylation (data not shown). STAT1 protein expression, however, did not change under these conditions (lanes 3 and 4) .
Following expression of the known IFN␥:STAT1-target genes, IP-10 and ICAM-1 (3, 23) , under these conditions (Fig.  1C) unraveled a protein synthesis-dependent effect for IP-10 and a potential protein synthesis-independent effect for ICAM-1 (lanes 3 and 4) .
IFN␥ sensitizes ECs for LPS-induced STAT1-phosphorylation and target gene expression. Next, we studied the possibility of STAT1-dependent cross talk in ECs between LPS and IFN␥. Based on the IFN␥ and LPS time-course experiments (see above), we decided to use the IFN␥ for 8 h (10 ng/ml) and LPS for 4 h (1 g/ml) to study the effect of IFN␥ pretreatment on LPS signaling. Indeed, we observed that pretreatment of HMECs with IFN␥ for 4 h followed by LPS for another 4 h (see Fig. 2A ) resulted in a significant increase in STAT1 phosphorylation compared with both factors alone (compare lane 4 with 2 and 3). Increased STAT1 protein levels, strictly dependent on IFN␥ ( Fig. 2A; lanes 4, 2 ,3) , could provide a possible explanation for the augmented STAT1 phosphorylation under conditions when both IFN␥ and LPS are present.
Similarly, IP-10 and ICAM-1 were identified as IFN␥-as well as LPS-inducible genes, which coincided with STAT1 phosphorylation. Moreover, increased mRNA (Fig. 2B) and protein (Fig. 2C ) levels of both IP-10 and ICAM-1 could be detected in HMECs pretreated with IFN␥ for 4 h followed by LPS for another 4 h, compared with both factors alone (compare lane 4 with 2 and 3).
In ECs STAT1-mediated cross talk between IFN␥ and LPS is protein-synthesis dependent. As can be depicted from Fig. 3A , the increase in STAT1 phosphorylation observed in HMECs treated with IFN␥ for 4 h followed by LPS for 4 h (lanes 1-4) is blocked in the presence of cycloheximide (lanes 5-8), which correlates with a protein synthesis-dependent mechanism. More important, cycloheximide also inhibited IFN␥-mediated increase in STAT1 protein levels ( Fig. 3A; lanes 1-4, 5-8 ), providing additional evidence that augmented STAT1 phosphorylation under conditions when both IFN␥ and LPS are present is dependent on STAT1 protein synthesis.
Fludarabine attenuates STAT1-dependent cross talk between IFN␥ and LPS and expression of IP-10 and ICAM-1. To obtain further evidence for a direct role of STAT1 in cross talk between IFN␥ and LPS, we first treated HMECs with IFN␥, LPS, or both in the absence or presence of the STAT1-inhibitor fludarabine. As such, fludarabine was able to partially prevent the augmented effect of IFN␥ on LPS-induced STAT1 phosphorylation and STAT1 expression but almost completely abolished IRF1 expression ( Fig. 3B; lanes 1-4, 5-8) .
Fludarabine also affected gene expression of IP-10 and ICAM-1 in HMECs treated with IFN␥, LPS, or both, although in different ways (Fig. 3C) . The increase in IP-10 gene expression (Fig. 3C ) expression observed in HMECs treated with IFN␥ followed by LPS (lanes 1-4) was almost completely absent in the presence of fludarabine (lanes 5-8) , which coincided with IP-10 protein levels (Fig. 3D ) and correlates with a predominant STAT1-dependent mechanism. On the other hand, the increased gene expression of ICAM-1 (Fig. 3C ) was affected by fludarabine to a lesser extent, implicating only partial involvement of STAT1. Although ICAM-1 protein levels were rather low under these conditions, a comparable expression pattern could be detected (Fig. 3D) . 
h and then treated with LPS for 4 h (B and C). A and B:
protein extracts were analyzed by Western blot analysis for tyrosine phosphorylated STAT1, STAT1, and GAPDH. C: RNA was isolated and subjected to RT-PCR for interferon gamma-induced protein 10 kDa (IP-10) and ICAM-1. For all experiments n ϭ 3, graphs represent mean intensity of Western blot bands Ϯ SE. Data were tested for significancy by one-way ANOVA, followed by post-hoc Tukey HSD test. See text for more details.
In VSMCs STAT1-mediated cross talk between IFN␥ and LPS is TLR4 dependent. In analogy to ECs ( Fig. 2A) , we observed that pretreatment of VSMCs with IFN␥ for 4 h followed by LPS for another 4 h (see Fig. 4A ) also resulted in a significant increase in STAT1 phosphorylation compared with both factors alone (compare lane 4 with 2 and 3). Increased STAT1 protein levels, as in EC, were strictly dependent on IFN␥ ( Fig. 4A; compare lane 4 with 2 and 3) .
Moreover, in TLR4
Ϫ / Ϫ VSMCs, LPS was not able to phosphorylate STAT1 (Fig. 4A; lane 7) . As a consequence STAT1 phosphorylation was not increased under conditions when both IFN␥ and LPS were present, even though STAT1 expression was still upregulated by IFN␥ (lanes 5-8) .
mRNA levels of IP-10 in VSMCs followed the expression pattern of ECs, as they were upregulated by both IFN␥ and LPS and highly increased in the presence of both agents (see Fig. 4B ; lanes 1-4), coinciding with phosphorylated STAT1. Moreover, this happened in a TLR4-dependent fashion (lanes 5-8) . Under the same conditions, IP-10 protein secreted in the medium correlated with IP-10 mRNA levels (Fig. 4C) . Together, this implies that in both ECs and SMCs STAT1 provides a platform for cross talk between IFN␥ and LPS, which results in increased expression of pro-inflammatory target genes.
Fludarabine inhibits IFN␥-and LPS-dependent adhesion of monocytes to
ECs. Furthermore, we investigated whether the cross talk between IFN␥ and LPS in ECs would lead to increased adhesion of monocytes to ECs. Figure 5A shows that pretreatment of HMECs with IFN␥ for 4 h followed by LPS for another 4 h resulted in a significant increase in adhesion of U937 cells compared with both factors alone. As such, IFN␥ increased adhesion by about 15% and LPS alone by 50%. But when ECs were treated with both, adhesion of monocytes increased by 120% (Fig. 5A) . Interestingly, in the presence of fludarabine, adhesion of monocytes to HMECs, induced by treatment with IFN␥ followed by LPS, is decreased more than 70% (Fig. 5B) . This is indicative of a STAT1-dependent mechanism.
DISCUSSION
IFN␥ is vital for both innate and adaptive immunity and is also expressed at high levels in atherosclerotic lesions. As such IFN␥ plays a crucial role in the pathology of atherosclerosis through activation of STAT1. More recently, STAT1 has been identified as a point of convergence for the cross talk between IFN␥ and TLRs in immune cells (25) . To date, there is limited information available on the role of STAT1 in TLR4-mediated progression of atherosclerosis and on potential synergism between LPS and IFN␥ signaling in cells from the vasculature. In a recent expression profiling study of IFN␥-treated ECs, we identified the chronic inflammation indicators IP-10 and ICAM-1 among the highest IFN␥-inducible genes (3), and we were interested how these genes would behave in the signal integration between IFN␥ and LPS. Our results suggest that also in ECs and VSMCs STAT1 provides a platform for cross talk between IFN␥ and LPS, which results in STAT1-dependent EC and VSMC activation, increased expression of ICAM-1 and IP-10, and monocyte adhesion.
IFN␥ produced by T cells and NK cells is considered to enhance TLR signaling in DCs and macrophages for the efficient induction of inflammatory mediators to eliminate pathogens (25) . IFN␥ signaling is largely mediated by the latent cytosolic factor STAT1 that is activated during IFN␥-dependent JAK-STAT signaling (7, 35) . STAT1 activity requires phosphorylation at tyrosine701 (Y701) for dimerization and induction of IFN␥-dependent gene regulation. Typically, in macrophages LPS triggers STAT1 phosphorylation at Y701 in a delayed manner, which is mediated by the induction and subsequent autocrine activities of type I IFN (14) . This coincides with our findings in ECs and VSMCs, in which LPSinduced STAT1 phosphorylation is secondary to LPS-induced IFN-␤ (not shown) and abrogated in the presence of cycloheximide, which is indicative of a protein synthesis-dependent mechanism. In general it is believed that the transactivator ability of the macrophage STAT1 pool is superactivated upon stimulation with both IFN␥ and LPS, relative to either agonist alone (25) . Likewise, pretreatment of ECs as well as VSMCs with IFN␥ followed by LPS resulted in a significant increase in STAT1 phosphorylation compared with both factors alone. This was dependent on protein synthesis and did not occur in TLR4 Ϫ / Ϫ VSMCs. Moreover, increased production of STAT1 protein in these cells, strictly dependent on IFN␥, provides a potential mechanism resulting in augmented STAT1 phosphorylation under conditions when both IFN␥ and LPS are present. IP-10 (also denoted as CXCL10) is a monocyte and T-lymphocyte chemokine that is constitutively expressed at low levels in thymic, splenic, and lymphnode stroma; however, expression can be highly induced by interferons in leukocytes, such as monocytes and macrophages, as well as in nonleukocytes, including ECs and VSMCs (10, 11). IP-10 was also shown to potentiate leukocyte adhesion to endothelium (29) and to be a potent mitogenic and chemotactic factor for VSMCs (34) . A growing body of evidence suggests that IP-10 may play a role in chronic inflammatory diseases, including coronary artery disease and related manifestations of atherosclerosis (13, 19) .
ICAM-1 is an immunoglobulin-like cell adhesion molecule expressed by several cell types including leukocytes and ECs and VSMCs (17) . ICAM-1 is induced in response to inflammatory cytokines and enables EC monocyte as well as EC lymphocyte interactions. The expression of ICAM-1 has also been detected on VSMCs, indicating ability to interract with leukocytes by this mechanism (6) . As such, ICAM-1 is critical for the transmigration of leukocytes out of blood vessels and into tissues. More important, ICAM-1 is present in atherosclerotic lesions and is involved in their progression by retaining monocytes and macrophages within the lesion (6, 17) . The transcriptional regulation of both ICAM-1 and IP-10 has shown to involve several transcription factors, including STAT1, IRF1, and nuclear factor (NF)-B (4, 15, 21, 23, 27) . IRF1 expression is upregulated by IFN␥ in a STAT1-dependent manner and subsequently a major mediator of long-term (and protein-synthesis dependent) IFN␥ signaling. NF-B does not participate in IFN␥ signaling, but like IRF1 (as shown here), plays a direct role in pro-inflammatory pathways activated by LPS, IL-1␤, and tumore necrosis factor-␣ (TNF-␣). ylation, although in a different way. LPS-induced expression correlated with a protein synthesis-dependent effect for IP-10 and a potential protein synthesis-independent effect for ICAM-1. This suggested a differential role of STAT1 in LPS-mediated transcriptional regulation of IP-10 compared with that of ICAM-1, which was confirmed by experiments including fludarabine.
In case of IP-10, the dramatic increase in gene expression observed in ECs and VSMCs treated with IFN␥ followed by LPS was absent in TLR4 Ϫ / Ϫ cells and in the presence of fludarabine, which correlates with a predominant STAT1-dependent mechanism involved in the integration of both signals. Interestingly, the synergism between IFN␥ and IL1␤ or TNF-␣ in mouse embryonic fibroblasts (MEFs) and macrophages was shown to result in increased expression of IP-10 in a STAT1-dependent manner and requiring IRF1 but not NF-B (21, 26, 27) . Since a protein synthesis-dependent mechanism was involved and IRF1 is upregulated by both IFN␥ and LPS, it is tempting to speculate that a similar IRF1-mediated mechanism could play a role in IP-10 expression in IFN␥-primed vascular cells that are subsequently stimulated by LPS.
In contrast, the increased expression of ICAM-1 RNA in ECs treated with IFN␥ followed by LPS was weaker compared with IP-10 and only partially affected by fludarabine, implicating additional involvement of a STAT1-independent mechanism. This most likely involves NF-B, since the protein synthesisindependent character of NF-B activation by LPS is in agreement with the cycloheximide-independent expression of ICAM-1 under these conditions. IFN␥-induced ICAM-1 expression was shown to be STAT1 dependent (33) . Indeed the ICAM-1 promoter contains STAT1 and NF-B binding sites, and maximal transcription requires both signals (4, 15, 22, 31) . This suggests that a mechanism involving the cooperation between STAT1 (IFN␥ and LPS-mediated) and NF-B (strictly LPS mediated) is responsible for ICAM-1 expression in IFN␥-primed vascular cells that are subsequently stimulated by LPS.
Together, these mechanisms could provide an explanation for the differential STAT1-dependent IP-10 and ICAM-1 expression in the presence of both IFN␥ and TLR signals, relative to signaling with either agonist alone (also summarized in Fig. 6 ). Nevertheless, it does not exclude the possibility that other molecular mechanisms and other transcription factors may also be involved (25) .
Our observation that fludarabine was also able to inhibit IFN␥-and LPS-dependent protein expression of IP-10 and ICAM-1 as well as dramatically reduce adhesion of monocytes to ECs in vitro, is in line with a prominent role for both IP-10 and ICAM-1 in this phenomenon. Importantly, fludarabine induced significant reduction of STAT1 phosphorylation and expression in ECs in vitro, whereas it did not affect the expression and activation of STAT3 (data not shown) (9) . Thus these data strongly suggest that fludarabine inhibits adhesion of monocytes to ECs by specifically reducing STAT1 activation. Consequently, the signal integration between IFN␥ and LPS signaling may have important biological significance since both pathways are simultaneously activated during pathogenesis of atherosclerosis. Therefore, in the presence of IFN␥ and LPS (or any other exogenous or endogenous TLR4 ligands), IP-10 and ICAM-1 can be produced in ECs and VSMCs and may in turn function on leukocyte attraction and adhesion and VSMC proliferation and migration, which are important characteristics of EC dysfunction and early triggers of atherosclerosis.
With the established roles of IFN␥ and TLRs in atherosclerotic pathology, the synergism between IFN␥ and TLRs in ECs and VSMCs and atheroma-interacting immune cells in response to exogenous and endogenous atherogenic ligands could result in amplification of STAT1, IRF1, and NF-Bmediated pro-inflammatory responses in the damaged vessel and be a novel mechanism involved in EC dysfunction and the initiation and progression of atherosclerosis (Fig. 6 ). As such, STAT1 could potentially represent a novel target of therapeutic intervention that has a crucial role in mediating the interplay between damaged vessels and host immunity to control atherosclerosis mediated by IFN␥ and TLR-directed cross talk. 
